ISU Abxis Co Ltd
086890
Company Profile
Business description
ISU Abxis Co Ltd is engaged in developing and manufacturing therapeutic antibodies in South Korea. It offers Abciximab, Clotinab, Abcertin, and Fabagal used to treat incurable diseases such as cancer and rare diseases.
Contact
3Fl. Kookje Bldg
90-1 Daeshin-dong
Seodaemun-gu
Seoul120-160
KORT: +82 222278888
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
185
Stocks News & Analysis
stocks
This ASX supermarkets business is now underperforming its largest competitor
Competition restrains long-term margins.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,923.80 | 30.30 | -0.34% |
| CAC 40 | 7,976.12 | 138.72 | -1.71% |
| DAX 40 | 23,991.27 | 301.11 | -1.24% |
| Dow JONES (US) | 49,012.36 | 486.91 | -0.98% |
| FTSE 100 | 10,363.93 | 14.89 | -0.14% |
| HKSE | 26,095.88 | 319.35 | 1.24% |
| NASDAQ | 24,992.77 | 121.68 | -0.48% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,097.68 | 58.48 | 0.45% |
| S&P 500 | 7,191.60 | 38.52 | -0.53% |
| S&P/ASX 200 | 8,697.10 | 28.50 | -0.33% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |